Diabetes

Encina Commons, Room 220
615 Crothers Way
Stanford, CA 94305-6006

(650) 721-2486 (650) 723-1919
0
Professor, Health Policy
jeremy-fisch_profile_compressed.jpg PhD

Jeremy Goldhaber-Fiebert, PhD, is a Professor of Health Policy, a Core Faculty Member at the Center for Health Policy and the Department of Health Policy, and a Faculty Affiliate of the Stanford Center on Longevity and Stanford Center for International Development. His research focuses on complex policy decisions surrounding the prevention and management of increasingly common, chronic diseases and the life course impact of exposure to their risk factors. In the context of both developing and developed countries including the US, India, China, and South Africa, he has examined chronic conditions including type 2 diabetes and cardiovascular diseases, human papillomavirus and cervical cancer, tuberculosis, and hepatitis C and on risk factors including smoking, physical activity, obesity, malnutrition, and other diseases themselves. He combines simulation modeling methods and cost-effectiveness analyses with econometric approaches and behavioral economic studies to address these issues. Dr. Goldhaber-Fiebert graduated magna cum laude from Harvard College in 1997, with an A.B. in the History and Literature of America. After working as a software engineer and consultant, he conducted a year-long public health research program in Costa Rica with his wife in 2001. Winner of the Lee B. Lusted Prize for Outstanding Student Research from the Society for Medical Decision Making in 2006 and in 2008, he completed his PhD in Health Policy concentrating in Decision Science at Harvard University in 2008. He was elected as a Trustee of the Society for Medical Decision Making in 2011.

Past and current research topics:

  1. Type 2 diabetes and cardiovascular risk factors: Randomized and observational studies in Costa Rica examining the impact of community-based lifestyle interventions and the relationship of gender, risk factors, and care utilization.
  2. Cervical cancer: Model-based cost-effectiveness analyses and costing methods studies that examine policy issues relating to cervical cancer screening and human papillomavirus vaccination in countries including the United States, Brazil, India, Kenya, Peru, South Africa, Tanzania, and Thailand.
  3. Measles, haemophilus influenzae type b, and other childhood infectious diseases: Longitudinal regression analyses of country-level data from middle and upper income countries that examine the link between vaccination, sustained reductions in mortality, and evidence of herd immunity.
  4. Patient adherence: Studies in both developing and developed countries of the costs and effectiveness of measures to increase successful adherence. Adherence to cervical cancer screening as well as to disease management programs targeting depression and obesity is examined from both a decision-analytic and a behavioral economics perspective.
  5. Simulation modeling methods: Research examining model calibration and validation, the appropriate representation of uncertainty in projected outcomes, the use of models to examine plausible counterfactuals at the biological and epidemiological level, and the reflection of population and spatial heterogeneity.
CV
Date Label

Shorenstein APARC
Stanford University
Encina Hall E301
Stanford, CA 94305-6055

(650) 723-9072 (650) 723-6530
0
Senior Fellow at the Freeman Spogli Institute for International Studies
Professor, by courtesy, Health Policy
Faculty Research Fellow of the National Bureau of Economic Research
Faculty Affiliate at the Stanford Center on China's Economy and Institutions
karen-0320_cropprd.jpg PhD

Karen Eggleston is a Senior Fellow at the Freeman Spogli Institute for International Studies (FSI) at Stanford University and Director of the Stanford Asia Health Policy Program at the Shorenstein Asia-Pacific Research Center at FSI. She is also a Fellow with the Center for Innovation in Global Health at Stanford University School of Medicine, and a Faculty Research Fellow of the National Bureau of Economic Research (NBER). Her research focuses on government and market roles in the health sector and Asia health policy, especially in China, India, Japan, and Korea; healthcare productivity; and the economics of the demographic transition.

Eggleston earned her PhD in public policy from Harvard University and has MA degrees in economics and Asian studies from the University of Hawaii and a BA in Asian studies summa cum laude (valedictorian) from Dartmouth College. Eggleston studied in China for two years and was a Fulbright scholar in Korea. She served on the Strategic Technical Advisory Committee for the Asia Pacific Observatory on Health Systems and Policies and has been a consultant to the World Bank, the Asian Development Bank, and the WHO regarding health system reforms in the PRC.

Director, Asia Health Policy Program at the Walter H. Shorenstein Asia-Pacific Research Center
Stanford Health Policy Associate
CV
Date Label
Authors
Donald Kennedy
News Type
Commentary
Date
Paragraphs

The national debate over human embryonic stem cell research -- one that has pitted religious objections against the promise of major scientific and therapeutic advances -- has been reawakened by a dramatic advance that could have been made in the United States, but wasn't. That's because on Aug. 9, 2001, President Bush announced that only stem cell lines obtained before that date could be used in research supported by federal funds. This has virtually halted a vital area of medical science here because development of an equivalent level of private support will require many years. And that's why the new excitement comes from South Korea, not from this country. The stakes are high. Stem cells, which can be obtained from human embryos otherwise discarded at fertility clinics in the course of assisted reproduction, are capable of forming all of the tissues of the adult human body under the right circumstances. They are of enormous potential advantage in the treatment of Parkinson's disease, spinal cord injuries, Alzheimer's disease and diabetes. So what's wrong with the dozen or so old cell lines we have? The problem is that most of the approved lines are unavailable, or otherwise guarded by murky intellectual property claims. The way they were made and their limited genetic diversity limit their therapeutic utility. More important, new technology has taken us beyond their capacity. The recent experiments performed in South Korea have produced a robust line of stem cells, derived from blastocysts that were produced by activating eggs taken from female volunteers with nuclei taken from body cells of the donor. This process, called somatic cell nuclear transfer, is viewed by some as akin to cloning people, which no one in the scientific community favors. Instead, it provides a way to explore the early processes of human development and develop novel ways of understanding the basis for genetic predisposition to late-onset diseases. It is essential research, and it is needed here. Yet if the congressional opponents of stem cell research have their way, a bill already passed by the House and now being considered in the Senate would make such work a crime. In South Korea, cloning for reproductive purposes is against the law. But this work, plainly aimed at scientific and therapeutic purposes, was encouraged and supported by the government. If we decide to discourage or even criminalize such experiments here, they will be done elsewhere -- and the benefits will be reaped by others. One option in this country is to approach a solution at the state level. Some states have passed laws that make cloning people illegal but allow cloning stem cells -- an important distinction that Congress has so far been unwilling to make. And some states have developed the means for raising funds to support the kind of research that now cannot be done with federal funds. A forthcoming ballot initiative in California would appropriate $350 million each year to support stem cell research. It would create a California Stem Cell Research and Cures Fund, to be distributed by an Institute for Regenerative Medicine, overseen by an independent citizens committee selected from academic and research institutions. The funding plan rests on the authorization of a $3 billion general obligation bond issue. For the first five years, a positive tax revenue stream generated by the initial expenditures will make it possible not to burden the state's general fund while it recovers from its present economic stress. The California experiment is an interesting one. As Californians and scientists, we hope for its success. But we also hope that it will be a signal for other citizens -- that there are domestic alternatives to a national policy that threatens to drive an important and valuable research activity overseas. A California resolution would be nice for us, and for the California economy. But if we can't find a solution that permits stem cell research at the federal level, the result will be costly for our national health.

  • DAVID BALTIMORE is president of the California Institute of Technology;
  • PAUL BERG is a professor of biochemistry at Stanford University;
  • DONALD KENNEDY, former Stanford president, is editor-in-chief of Science magazine; and
  • IRV WEISSMAN is a professor of cancer biology at Stanford. They wrote this column for the Mercury News.
All News button
1

This project aims to develop a standardized computational framework for clinical practice guideline specification that will allow text guidelines to be easily translated into computable formats by clinical domain experts. These computable guidelines will then be directly applicable to real-time clinical decision support and to retrospective quality assessment of electronic medical records.

Subscribe to Diabetes